Form 4 for ABCL AbCellera Biologics Inc.
Accepted 2021-12-10 00:00:00 ET · period of report 2021-12-10 · accession 0001209191-21-069084 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-10 | 2021-12-10 | ABCL | Booth Andrew | CFO | M - OptEx | $0.32 | +500.0K | 553.5K | +935% | +$160.0K |
| D | 2021-12-10 | 2021-12-10 | ABCL | Booth Andrew | CFO | M - OptEx | $0.00 | -500.0K | 5.38M | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2021-12-10 | M | A | 500,000 | $0.32 | 553,500 | D | — | — | |
| 2 | Derivative | Share Options (right to buy) | 2021-12-10 | M | D | 500,000 | $0.00 | 5,384,820 | D | $0.32 · 2020-03-23 to 2029-08-22 | 500,000 Common Shares |